Telehealth transcranial direct current stimulation for recovery from Post-Acute Sequelae of SARS-CoV-2 (PASC) [Letter]
Eilam-Stock, Tehila; George, Allan; Lustberg, Matthew; Wolintz, Robyn; Krupp, Lauren B; Charvet, Leigh E
COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center
Parrotta, Erica; Kister, Ilya; Charvet, Leigh; Sammarco, Carrie; Saha, Valerie; Charlson, Robert Erik; Howard, Jonathan; Gutman, Josef Maxwell; Gottesman, Malcolm; Abou-Fayssal, Nada; Wolintz, Robyn; Keilson, Marshall; Fernandez-Carbonell, Cristina; Krupp, Lauren B; Zhovtis Ryerson, Lana
OBJECTIVE:To report outcomes on patients with multiple sclerosis (MS) and related disorders with coronavirus disease 2019 (COVID-19) illness. METHODS:From March 16 to April 30, 2020, patients with MS or related disorders at NYU Langone MS Comprehensive Care Center were identified with laboratory-confirmed or suspected COVID-19. The diagnosis was established using a standardized questionnaire or by review of in-patient hospital records. RESULTS:We identified 76 patients (55 with relapsing MS, of which 9 had pediatric onset; 17 with progressive MS; and 4 with related disorders). Thirty-seven underwent PCR testing and were confirmed positive. Of the entire group, 64 (84%) patients were on disease-modifying therapy (DMT) including anti-CD20 therapies (n = 34, 44.7%) and sphingosine-1-phosphate receptor modulators (n = 10, 13.5%). The most common COVID-19 symptoms were fever and cough, but 21.1% of patients had neurologic symptom recrudescence preceding or coinciding with the infection. A total of 18 (23.7%) were hospitalized; 8 (10.5%) had COVID-19 critical illness or related death. Features more common among those hospitalized or with critical illness or death were older age, presence of comorbidities, progressive disease, and a nonambulatory status. No DMT class was associated with an increased risk of hospitalization or fatal outcome. CONCLUSIONS:Most patients with MS with COVID-19 do not require hospitalization despite being on DMTs. Factors associated with critical illness were similar to the general at-risk patient population. DMT use did not emerge as a predictor of poor COVID-19 outcome in this preliminary sample.
Acute Diplopia as the Presenting Sign of Silent Sinus Syndrome
Saffra, Norman; Rakhamimov, Aleksandr; Saint-Louis, Leslie A; Wolintz, Robyn J
Silent sinus syndrome is a rare acquired condition that typically presents as enophthalmos and hypoglobus due to atelectasis of the maxillary sinus. The chronic negative pressure in the sinus slowly retracts the orbital floor, altering orbital anatomy and affecting the function of orbital contents. The authors present the first case of acute vertical diplopia as the presenting symptom of silent sinus syndrome.
Arthur H. Wolintz, MD (1937-2011) In Memoriam [Biography]
Wolintz, Robyn J
Isocoric pupil dysfunction
Wolintz, Robyn J
Dronabinol reduces signs and symptoms of idiopathic intracranial hypertension: a case report [Case Report]
Raby, Wilfrid Noel; Modica, Patricia A; Wolintz, Robyn J; Murtaugh, Kevin
A case is presented in which a woman diagnosed with a longstanding history of idiopathic intracranial hypertension reported improvement of frontal headaches, photophobia, transient blindness, enlarged blind spots, and tinnitus after smoking marijuana. All these symptoms and signs were associated with increased intracranial pressure (220-425 mm of water). Treatment with dronabinol at a dose of 10 mg twice a day, then reduced to 5 mg twice a day, relieved all of her symptoms. Previously noted papilledema and enlargement of blind spots also resolved, and this, in the absence of psychoactive effect or weight gain.
Carotid endarterectomy for ophthalmic manifestations: is it ever indicated?
Wolintz, Robyn J
Four ophthalmic manifestations make up a substantial proportion of the indications for carotid endarterectomy (CE). They include transient monocular visual loss (TMVL), ocular ischemic syndrome (OIS), retinal artery occlusion (RAO), and asymptomatic Hollenhorst plaque. Critical review of the literature shows that the evidence to support the efficacy of CE in these four settings is tenuous.
Common errors in the use of magnetic resonance imaging for neuro-ophthalmic diagnosis [Case Report]
Wolintz, R J; Trobe, J D; Cornblath, W T; Gebarski, S S; Mark, A S; Kolsky, M P
The optimal utilization of magnetic resonance imaging in neuro-ophthalmic diagnosis is limited by errors in prescribing and interpreting scans. In a review of case material, we discovered four common prescriptive errors: 1) failure to apply a dedicated study, 2) inappropriate use of a dedicated study, 3) omission of intravenous contrast, and 4) omission of specialized sequences. The four common interpretive errors were the following: 1) failure to detect the lesion because of misleading clinical information, 2) rejection of a clinical diagnosis because an expected imaging abnormality was absent, 3) assumption that a striking imaging abnormality accounted for the clinical abnormality, and 4) failure to consider the lack of clinical specificity of imaging abnormalities. Many of these errors could be avoided by improved communication between clinicians and radiologists.